Considering the less toxicity and widely use of cytarabine in AML patients, we explored the mechanisms of venetoclax and cytarabine combination by focusing Bim-mediated apoptosis, DNA damage and Mcl-1 regulation. This evidence concerns the gene BCL2L11 and acute myeloid leukemia.